BioSpace News Archive

Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced that it plans to release its third quarter earnings results after market close on Thursday, November 19, 2020.

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced its financial results for the three months ended September 30, 2020 and provided a corporate update.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, reported financial results for the third quarter of 2020.

GenMark Diagnostics, Inc., a leading provider of automated, multiplex molecular diagnostic testing systems, announced that the company plans to participate in the upcoming Canaccord Virtual MedTech & Diagnostics Forum.

Acutus Medical, Inc., announced that its management will participate at the upcoming Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020.

Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection Product and Therapy Product Revenue Growth of 44% and 251%, Respectively

OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease Remains on Track for Q4 2020

Company to host conference call and webcast with KOLs to discuss new data from Cohorts 1-4 of OPTIC Phase 1 trial of ADVM-022 for wet AMD on November 14, 2020 at 7:30 am PT

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and nine months ended September 30, 2020.

Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases, reported financial results for the third quarter ended September 30, 2020 and provided business highlights.